Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

Chimeric antigen receptor (CAR) modified T cells targeted CD19 showed promising clinical outcomes in treatment of B cell malignances such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and other indolent lymphomas. However, the clinical benefit varies tremendously among di...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Zhang, Tengfei, Cao, Ling, Xie, Jing, Shi, Ni, Zhang, Zhen, Luo, Zhenzhen, Yue, Dongli, Zhang, Zimeng, Wang, Liping, Han, Weidong, Xu, Zhongwei, Chen, Hu, Zhang, Yi
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Clinical Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741817/
https://ncbi.nlm.nih.gov/pubmed/26376680
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires